biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by KayakerBCon Sep 19, 2016 7:35pm

123 Views

Post# 25253934

RE:RE:RE:Note to John Carroll and Investors...

its naturally occurring in the human body.....like human growth hormone is....when athletes abuse hgh there has been no toxicity rrported. ..my thoughts are that the same would occur with transcend.

You have no basis for concluding that there will be "no toxicity" from melanotransferrin because there is none from HGH. (By the way, you might want to look at the long list of side effects from HGH).

Have you ever researched melanotransferrin? Give it a go on Google Scholar. My bet is you'll come back with more questions than answers.

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute